MARKET

OTLK

OTLK

Outlook Therapeutics Inc
NASDAQ
0.7564
-0.1324
-14.90%
After Hours: 0.7989 +0.0425 +5.62% 19:59 08/14 EDT
OPEN
0.8438
PREV CLOSE
0.8888
HIGH
0.8438
LOW
0.7120
VOLUME
104.62M
TURNOVER
--
52 WEEK HIGH
3.390
52 WEEK LOW
0.1611
MARKET CAP
142.08M
P/E (TTM)
-0.6009
1D
5D
1M
3M
1Y
5Y
1D
Outlook Therapeutics Price Target Maintained With a $4.00/Share by BTIG
Dow Jones · 1d ago
BTIG Reiterates Buy on Outlook Therapeutics, Maintains $4 Price Target
Benzinga · 1d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 1d ago
Outlook Therapeutics Reports Q3 Net Loss; Advances U.S. Launch Of LYTENAVA
NASDAQ · 1d ago
Transcript: Outlook Therapeutics Q3 2026 Earnings Conference Call
Benzinga · 1d ago
Outlook Therapeutics Announces $55 Million Equity Offering
TipRanks · 1d ago
Outlook Therapeutics Q3 Adj. EPS $(0.09), Inline, Sales $9.000K Miss $5.300M Estimate
Benzinga · 1d ago
Outlook Therapeutics Non-GAAP EPS of -$0.09 misses by $0.02, revenue of $0.01M misses by $0.96M
Seeking Alpha · 1d ago
More
About OTLK
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.

Webull offers Outlook Therapeutics Inc stock information, including NASDAQ: OTLK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTLK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OTLK stock methods without spending real money on the virtual paper trading platform.